T1	Participants 78 117	a double-blind placebo-controlled study
T2	Participants 122 230	6 week double-blind placebo-controlled trial of cyproheptadine augmentation of ongoing haloperidol treatment
T3	Participants 248 284	40 chronic schizophrenic in-patients
